![]() ![]() 18% of prescriptions for these drugs filled in NM in 2013 were refills, and 4% were refills beyond the 2nd refill. Prescribers cannot authorize refills of hydrocodone combination products after October 6, 2014.The main impacts likely to be seen by consumers are: Hydrocodone was only available in hydrocodone combination products in 2013. In New Mexico, the most common prescription opioid drugs involved in 2013 deaths were oxycodone (98 deaths), morphine (53), hydrocodone (48), methadone (29) and fentanyl (13). An FDA Drug Safety and Risk Management Advisory Committee concluded that these drugs meet the criteria for the more restrictive categorization and recommended that the DEA reschedule them. The addition of non-narcotic ingredients does not diminish the abuse potential of these products. A federal analysis shows that hydrocodone combination products have a high potential for abuse, and abuse may lead to severe psychological or physical dependence. The Controlled Substances Act places drugs with accepted medical uses and the greatest potential for harm and abuse in Schedule II. More than 721,000 prescriptions for these products were dispensed in New Mexico in 2013, totaling 41% of all opioid prescriptions filled. Hydrocodone combination products are the most commonly prescribed opioid pain relief drugs. Brand names include Vicodin, Lorcet, Norco, and Tussionex. Drugs that include hydrocodone are used to treat moderate to severe pain and relieve cough. Hydrocodone combination products are drugs that contain hydrocodone and another substance, such as acetaminophen or aspirin. Starting today, the Drug Enforcement Administration ( DEA) is treating hydrocodone combination products as a more restrictive category of controlled substances (Schedule II from Schedule III). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |